Noninferiority  ||| S:0 E:15 ||| NNP
of  ||| S:15 E:18 ||| IN
incobotulinumtoxinA ||| S:18 E:37 ||| NNP
,  ||| S:37 E:39 ||| ,
free  ||| S:39 E:44 ||| JJ
from  ||| S:44 E:49 ||| IN
complexing  ||| S:49 E:60 ||| JJ
proteins ||| S:60 E:68 ||| NNS
,  ||| S:68 E:70 ||| ,
compared  ||| S:70 E:79 ||| VBN
with  ||| S:79 E:84 ||| IN
another  ||| S:84 E:92 ||| DT
botulinum  ||| S:92 E:102 ||| JJ
toxin  ||| S:102 E:108 ||| NN
type  ||| S:108 E:113 ||| NN
A  ||| S:113 E:115 ||| NN
in  ||| S:115 E:118 ||| IN
the  ||| S:118 E:122 ||| DT
treatment  ||| S:122 E:132 ||| NN
of  ||| S:132 E:135 ||| IN
glabellar  ||| S:135 E:145 ||| JJ
frown  ||| S:145 E:151 ||| JJ
lines  ||| S:151 E:157 ||| NNS
Use  ||| S:157 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
botulinum  ||| S:164 E:174 ||| JJ
toxin  ||| S:174 E:180 ||| NN
for  ||| S:180 E:184 ||| IN
esthetic  ||| S:184 E:193 ||| JJ
purposes  ||| S:193 E:202 ||| NNS
has  ||| S:202 E:206 ||| VBZ
rapidly  ||| S:206 E:214 ||| RB
expanded  ||| S:214 E:223 ||| VBN
over  ||| S:223 E:228 ||| IN
the  ||| S:228 E:232 ||| DT
last  ||| S:232 E:237 ||| JJ
20  ||| S:237 E:240 ||| CD
years ||| S:240 E:245 ||| NNS
.  ||| S:245 E:247 ||| .
IncobotulinumtoxinA ||| S:247 E:266 ||| NNP
,  ||| S:266 E:268 ||| ,
also  ||| S:268 E:273 ||| RB
known  ||| S:273 E:279 ||| VBN
as  ||| S:279 E:282 ||| IN
NT  ||| S:282 E:285 ||| NNP
201 ||| S:285 E:288 ||| CD
,  ||| S:288 E:290 ||| ,
is  ||| S:290 E:293 ||| VBZ
a  ||| S:293 E:295 ||| DT
new  ||| S:295 E:299 ||| JJ
botulinum  ||| S:299 E:309 ||| JJ
toxin  ||| S:309 E:315 ||| NN
type  ||| S:315 E:320 ||| NN
A  ||| S:320 E:322 ||| DT
( ||| S:322 E:323 ||| -LRB-
150  ||| S:323 E:327 ||| CD
kDa ||| S:327 E:330 ||| NN
)  ||| S:330 E:332 ||| -RRB-
that  ||| S:332 E:337 ||| WDT
is  ||| S:337 E:340 ||| VBZ
free  ||| S:340 E:345 ||| JJ
from  ||| S:345 E:350 ||| IN
complexing  ||| S:350 E:361 ||| JJ
proteins ||| S:361 E:369 ||| NNS
.  ||| S:369 E:371 ||| .
A  ||| S:371 E:373 ||| DT
prospective ||| S:373 E:384 ||| JJ
,  ||| S:384 E:386 ||| ,
multicenter ||| S:386 E:397 ||| NN
,  ||| S:397 E:399 ||| ,
randomized ||| S:399 E:409 ||| NN
,  ||| S:409 E:411 ||| ,
rater-  ||| S:411 E:418 ||| JJ
and  ||| S:418 E:422 ||| CC
patient-blind ||| S:422 E:435 ||| JJ
,  ||| S:435 E:437 ||| ,
international  ||| S:437 E:451 ||| JJ
Phase  ||| S:451 E:457 ||| NNP
III  ||| S:457 E:461 ||| NNP
trial  ||| S:461 E:467 ||| NN
to  ||| S:467 E:470 ||| TO
investigate  ||| S:470 E:482 ||| VB
the  ||| S:482 E:486 ||| DT
noninferiority  ||| S:486 E:501 ||| NN
of  ||| S:501 E:504 ||| IN
incobotulinumtoxinA  ||| S:504 E:524 ||| JJ
to  ||| S:524 E:527 ||| TO
another  ||| S:527 E:535 ||| DT
botulinum  ||| S:535 E:545 ||| JJ
toxin  ||| S:545 E:551 ||| NN
type  ||| S:551 E:556 ||| NN
A ||| S:556 E:557 ||| NN
,  ||| S:557 E:559 ||| ,
onabotulinumtoxinA ||| S:559 E:577 ||| NNP
,  ||| S:577 E:579 ||| ,
in  ||| S:579 E:582 ||| IN
the  ||| S:582 E:586 ||| DT
treatment  ||| S:586 E:596 ||| NN
of  ||| S:596 E:599 ||| IN
glabellar  ||| S:599 E:609 ||| JJ
frown  ||| S:609 E:615 ||| JJ
lines ||| S:615 E:620 ||| NNS
.  ||| S:620 E:622 ||| .
A  ||| S:622 E:624 ||| DT
total  ||| S:624 E:630 ||| NN
of  ||| S:630 E:633 ||| IN
381  ||| S:633 E:637 ||| CD
patients  ||| S:637 E:646 ||| NNS
were  ||| S:646 E:651 ||| VBD
randomized  ||| S:651 E:662 ||| VBN
in  ||| S:662 E:665 ||| IN
a  ||| S:665 E:667 ||| DT
3 ||| S:667 E:668 ||| CD
: ||| S:668 E:669 ||| :
1  ||| S:669 E:671 ||| CD
( ||| S:671 E:672 ||| -LRB-
incobotulinumtoxinA ||| S:672 E:691 ||| NNP
: ||| S:691 E:692 ||| :
onabotulinumtoxinA ||| S:692 E:710 ||| NNP
)  ||| S:710 E:712 ||| -RRB-
ratio  ||| S:712 E:718 ||| NN
to  ||| S:718 E:721 ||| TO
receive  ||| S:721 E:729 ||| VB
24  ||| S:729 E:732 ||| CD
U  ||| S:732 E:734 ||| NNP
incobotulinumtoxinA  ||| S:734 E:754 ||| NNP
of  ||| S:754 E:757 ||| IN
or  ||| S:757 E:760 ||| CC
onabotulinumtoxinA ||| S:760 E:778 ||| JJ
.  ||| S:778 E:780 ||| .
Efficacy  ||| S:780 E:789 ||| JJ
end  ||| S:789 E:793 ||| NN
points  ||| S:793 E:800 ||| NNS
included  ||| S:800 E:809 ||| VBD
the  ||| S:809 E:813 ||| DT
percentage  ||| S:813 E:824 ||| NN
of  ||| S:824 E:827 ||| IN
responders  ||| S:827 E:838 ||| NNS
( ||| S:838 E:839 ||| -LRB-
patients  ||| S:839 E:848 ||| NNS
with  ||| S:848 E:853 ||| IN
an  ||| S:853 E:856 ||| DT
improvement  ||| S:856 E:868 ||| NN
of  ||| S:868 E:871 ||| IN
â‰¥1  ||| S:871 E:874 ||| CD
point  ||| S:874 E:880 ||| NN
on  ||| S:880 E:883 ||| IN
a  ||| S:883 E:885 ||| DT
4-point  ||| S:885 E:893 ||| JJ
facial  ||| S:893 E:900 ||| JJ
wrinkle  ||| S:900 E:908 ||| NN
scale ||| S:908 E:913 ||| NN
)  ||| S:913 E:915 ||| -RRB-
at  ||| S:915 E:918 ||| IN
maximum  ||| S:918 E:926 ||| JJ
frown  ||| S:926 E:932 ||| NN
at  ||| S:932 E:935 ||| IN
weeks  ||| S:935 E:941 ||| NNS
4  ||| S:941 E:943 ||| CD
and  ||| S:943 E:947 ||| CC
12  ||| S:947 E:950 ||| CD
as  ||| S:950 E:953 ||| IN
assessed  ||| S:953 E:962 ||| VBN
by  ||| S:962 E:965 ||| IN
the  ||| S:965 E:969 ||| DT
investigators ||| S:969 E:982 ||| NNS
,  ||| S:982 E:984 ||| ,
and  ||| S:984 E:988 ||| CC
a  ||| S:988 E:990 ||| DT
panel  ||| S:990 E:996 ||| NN
of  ||| S:996 E:999 ||| IN
independent  ||| S:999 E:1011 ||| JJ
raters  ||| S:1011 E:1018 ||| NNS
based  ||| S:1018 E:1024 ||| VBN
on  ||| S:1024 E:1027 ||| IN
standardized  ||| S:1027 E:1040 ||| JJ
digital  ||| S:1040 E:1048 ||| JJ
photographs ||| S:1048 E:1059 ||| NNS
.  ||| S:1059 E:1061 ||| .
Four  ||| S:1061 E:1066 ||| CD
weeks  ||| S:1066 E:1072 ||| NNS
after  ||| S:1072 E:1078 ||| IN
injection ||| S:1078 E:1087 ||| NN
,  ||| S:1087 E:1089 ||| ,
response  ||| S:1089 E:1098 ||| NN
rates  ||| S:1098 E:1104 ||| NNS
at  ||| S:1104 E:1107 ||| IN
maximum  ||| S:1107 E:1115 ||| JJ
frown  ||| S:1115 E:1121 ||| NN
were  ||| S:1121 E:1126 ||| VBD
96.4 ||| S:1126 E:1130 ||| CD
%  ||| S:1130 E:1132 ||| NN
in  ||| S:1132 E:1135 ||| IN
the  ||| S:1135 E:1139 ||| DT
incobotulinumtoxinA  ||| S:1139 E:1159 ||| JJ
group  ||| S:1159 E:1165 ||| NN
and  ||| S:1165 E:1169 ||| CC
95.7 ||| S:1169 E:1173 ||| CD
%  ||| S:1173 E:1175 ||| NN
in  ||| S:1175 E:1178 ||| IN
the  ||| S:1178 E:1182 ||| DT
onabotulinumtoxinA  ||| S:1182 E:1201 ||| JJ
group  ||| S:1201 E:1207 ||| NN
as  ||| S:1207 E:1210 ||| IN
assessed  ||| S:1210 E:1219 ||| VBN
by  ||| S:1219 E:1222 ||| IN
independent  ||| S:1222 E:1234 ||| JJ
raters ||| S:1234 E:1240 ||| NN
.  ||| S:1240 E:1242 ||| .
Analysis  ||| S:1242 E:1251 ||| NN
of  ||| S:1251 E:1254 ||| IN
the  ||| S:1254 E:1258 ||| DT
data  ||| S:1258 E:1263 ||| NNS
confirmed  ||| S:1263 E:1273 ||| VBD
the  ||| S:1273 E:1277 ||| DT
noninferiority  ||| S:1277 E:1292 ||| NN
of  ||| S:1292 E:1295 ||| IN
incobotulinumtoxinA ||| S:1295 E:1314 ||| JJ
.  ||| S:1314 E:1316 ||| .
Response  ||| S:1316 E:1325 ||| NN
rates  ||| S:1325 E:1331 ||| NNS
at  ||| S:1331 E:1334 ||| IN
rest  ||| S:1334 E:1339 ||| NN
were  ||| S:1339 E:1344 ||| VBD
lower  ||| S:1344 E:1350 ||| JJR
for  ||| S:1350 E:1354 ||| IN
both  ||| S:1354 E:1359 ||| DT
products ||| S:1359 E:1367 ||| NNS
.  ||| S:1367 E:1369 ||| .
The  ||| S:1369 E:1373 ||| DT
rate  ||| S:1373 E:1378 ||| NN
of  ||| S:1378 E:1381 ||| IN
adverse  ||| S:1381 E:1389 ||| JJ
events  ||| S:1389 E:1396 ||| NNS
was  ||| S:1396 E:1400 ||| VBD
low ||| S:1400 E:1403 ||| JJ
.  ||| S:1403 E:1405 ||| .
IncobotulinumtoxinA  ||| S:1405 E:1425 ||| NNP
is  ||| S:1425 E:1428 ||| VBZ
equally  ||| S:1428 E:1436 ||| RB
as  ||| S:1436 E:1439 ||| IN
effective  ||| S:1439 E:1449 ||| JJ
as  ||| S:1449 E:1452 ||| IN
onabotulinumtoxinA  ||| S:1452 E:1471 ||| JJ
in  ||| S:1471 E:1474 ||| IN
the  ||| S:1474 E:1478 ||| DT
treatment  ||| S:1478 E:1488 ||| NN
of  ||| S:1488 E:1491 ||| IN
glabellar  ||| S:1491 E:1501 ||| JJ
frown  ||| S:1501 E:1507 ||| JJ
lines ||| S:1507 E:1512 ||| NNS
.  ||| S:1512 E:1514 ||| .
Both  ||| S:1514 E:1519 ||| DT
preparations  ||| S:1519 E:1532 ||| NN
were  ||| S:1532 E:1537 ||| VBD
well  ||| S:1537 E:1542 ||| RB
tolerated ||| S:1542 E:1551 ||| VBN
.  ||| S:1551 E:1553 ||| .
